The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis (PrEP) in low- and middle-income countries - PubMed
18 hours ago
- #HIV PrEP
- #cost estimation
- #low-and-middle-income countries
- MK-8527, a novel once-monthly oral PrEP for HIV, could be generically produced at an estimated cost of $4.49 per person-year in LMICs.
- The cost estimate is based on API shipment data and cost-plus modeling, with sensitivity analysis showing a range of $4.46-$24.91 per person-year.
- This estimated cost is significantly below existing PrEP cost-effectiveness thresholds of around $100-$200 per person-year in high-incidence settings.
- Equitable access to MK-8527 in LMICs will depend more on intellectual property and licensing agreements than on production feasibility.
- Early voluntary licensing agreements could enable timely generic availability and affordable global scale-up if clinical efficacy is confirmed.